Feb 19, 2026
The use of DAT for immunotherapies
Life Sciences, Immunology
- Supports development of precision microbiome therapies based on metabolite production or encapsulation
- Optimizes microbiota-shaped T-cell therapies like CAR-T and immune checkpoint inhibitors
- Mitigates GvHD severity and relapse via microbiome modulation
- Metabolite-based prediction of patient outcomes post-allo-HSCT
Your contact
Dr. Nicola Hoesch
- E-Mail:
- nhoesch@baypat.de
- Phone:
- +49 (0) 89 5480177 - 29
- Reference Number:
- B84103
Factsheet
Download Tech Offer (PDF)Challenge
Immunotherapies are crucial for cancer prevention and treatment but remain limited in efficacy. Allogeneic hematopoietic stem cell transplantation (allo‑HSCT) can cure many otherwise incurable hematological cancers, yet success is constrained by severe graft‑versus‑host disease (GvHD) and the persistent difficulty of reliably predicting survival and relapse after allo‑HSCT.
Innovation
The invention improves allo‑HSCT outcomes by leveraging the microbiome and its metabolites to modulate graft‑versus‑host disease (GvHD) while preserving graft‑versus‑leukemia (GvL) effects. Integrated analyses in allo‑HSCT patients identified a microbiome signature correlating with immuno‑modulatory metabolites (IMMs) and improved survival, summarized by the Immuno‑modulatory Metabolite Risk Index (IMM‑RI). Preclinical data show DAT promotes intestinal regeneration and balances GvL/GvHD via mTORC1‑ and STING‑dependent pathways.
Commercial Opportunities
Development Status
TLR03
